Adriana Orcesi Pedro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Adriana Orcesi Pedro has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Lucia Costa-Paiva
From the Department of Obstetrics and Gynecology, Faculty of Medical Sciences, State University of Campinas (FCM-UNICAMP), Campinas, São Paulo, Brazil
4 shared publications- Luiz Francisco Baccaro
Departamento de Tocoginecologia da Faculdade de Ciências Médicas da UNICAMP
4 shared publications Anna Valéria Gueldini de Moraes
Department of Obstetrics and Gynecology of Faculty of Medical Sciences, State University of Campinas (FCM-UNICAMP), Campinas, SP, Brazil
3 shared publications- Lúcia Costa-Paiva
Department of Obstetrics and Gynecology, Universidade Estadual de Campinas, Campinas, Sao Paulo, Brazil
3 shared publications Jeffrey Frederico Lui-Filho
Departament of Obstetrics and Gynecology, School of Medical Sciences, State University of Campinas (UNICAMP), Campinas, São Paulo, Brazil
2 shared publications- Luiza Borges Aguiar
Department of Obstetrics and Gynecology, State University of Campinas, Campinas, São Paulo, Brazil
2 shared publications
Latest Publications
- Open Access
- 25 March 2026
- Published by Federação das Associações de Ginecologia e Obstetrícia in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 48
Knowledge and practices of postmenopausal women regarding vitamin D and osteoporosis
Vitamin D has a direct influence on musculoskeletal health, and vitamin D deficiency is related to lower bone density and greater bone resorption and to a higher incidence of fractures. To assess knowledge, attitudes and practices regarding vitamin D and osteoporosis in postmenopausal women. This was a cross-sectional study carried out with 260 postmenopausal women who underwent routine consultations at the menopause outpatient clinic of Campinas State University-São Paulo. Women aged 50 years or older with amenorrhea for at least 12 months were included. From an interview, sociodemographic information and health data were collected, and knowledge about vitamin D, habits related to vitamin D, and knowledge about osteoporosis were evaluated using the Facts on Osteoporosis Quiz (FOOQ) questionnaire. A total of 67.31% of women answered less than half of the questions about knowledge of vitamin D, 58.85% performed their day-to-day activities mostly outdoors, and 53.85% said they did not expose themselves sufficiently to the sun in their daily lives. The average knowledge score on the FOOQ was 15.83 (± 3.75). The variables education level, number of correct FOOQ answers and total self-care score were associated with the highest score for knowledge of vitamin D. Knowledge about vitamin D and osteoporosis in this group of postmenopausal women was limited. High levels of education, knowledge about osteoporosis and self-care were factors associated with knowledge about vitamin D.
- 25 March 2026
- Published by Federação das Associações de Ginecologia e Obstetrícia in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 48
Open AccessKnowledge and practices of postmenopausal women regarding vitamin D and osteoporosis
Vitamin D has a direct influence on musculoskeletal health, and vitamin D deficiency is related to lower bone density and greater bone resorption and to a higher incidence of fractures. To assess knowledge, attitudes and practices regarding vitamin D and osteoporosis in postmenopausal women. This was a cross-sectional study carried out with 260 postmenopausal women who underwent routine consultations at the menopause outpatient clinic of Campinas State University-São Paulo. Women aged 50 years or older with amenorrhea for at least 12 months were included. From an interview, sociodemographic information and health data were collected, and knowledge about vitamin D, habits related to vitamin D, and knowledge about osteoporosis were evaluated using the Facts on Osteoporosis Quiz (FOOQ) questionnaire. A total of 67.31% of women answered less than half of the questions about knowledge of vitamin D, 58.85% performed their day-to-day activities mostly outdoors, and 53.85% said they did not expose themselves sufficiently to the sun in their daily lives. The average knowledge score on the FOOQ was 15.83 (± 3.75). The variables education level, number of correct FOOQ answers and total self-care score were associated with the highest score for knowledge of vitamin D. Knowledge about vitamin D and osteoporosis in this group of postmenopausal women was limited. High levels of education, knowledge about osteoporosis and self-care were factors associated with knowledge about vitamin D.
- 8 September 2025
- Published by Springer Nature in Osteoporosis International
- Vol. 36 (11) , 2221-2228
Latin American patients’ perceptions on osteoporosis diagnosis and treatment: The IOF Patient Advisory Group in Latin America
Summary The study explored osteoporosis patients’ views on the disease in six LATAM countries. All were diagnosed for over 3 years, 65% avoiding fragility fractures. Sixteen used osteoporosis drugs, trusting physicians most. Though osteoporosis has moderately impacted their quality of life, all fear a future of falls and loss of independence. Purpose The aim of this study was to understand osteoporosis patients’ perceptions, behaviors, and expectations in relation to diagnosis and treatment. Methods A convenience sample of 20 patients from six different LATAM countries constituted a focal group. All participants were diagnosed with osteoporosis and in treatment at various stages of the disease. The study was conducted in two phases: the first one involved a cross-sectional survey using an instrument developed by the IOF which was tailored to local needs, and the second consisted of a focus group in a hybrid format. Results The twenty participants were diagnosed with osteoporosis for less than 3 years, most of them received treatment and did not fracture. Treating physicians was the most trusted source of information, while influencers and media were seen as unreliable. Osteoporosis had a moderate impact on patients’ quality of life, with only a few requiring help with daily chores. The qualitative phase revealed that patients who received care at private institutions had better access to information about the disease and treatment options. Despite the minimal impact on their current quality of life, patients showed concern about future risks like falls and loss of independence. Conclusion Being diagnosed with osteoporosis has a significant impact on people’s daily life, independently whether a fracture occurred, received treatment, embraced a healthy bone lifestyle or trust own treating physician. Fear of fractures and their consequences underly patients’ perceptions which is seen as not considered enough by physicians, health authorities, drug companies, NGOs and media.
- 8 September 2025
- Published by Springer Nature in Osteoporosis International
- Vol. 36 (11) , 2221-2228
Latin American patients’ perceptions on osteoporosis diagnosis and treatment: The IOF Patient Advisory Group in Latin America
Summary The study explored osteoporosis patients’ views on the disease in six LATAM countries. All were diagnosed for over 3 years, 65% avoiding fragility fractures. Sixteen used osteoporosis drugs, trusting physicians most. Though osteoporosis has moderately impacted their quality of life, all fear a future of falls and loss of independence. Purpose The aim of this study was to understand osteoporosis patients’ perceptions, behaviors, and expectations in relation to diagnosis and treatment. Methods A convenience sample of 20 patients from six different LATAM countries constituted a focal group. All participants were diagnosed with osteoporosis and in treatment at various stages of the disease. The study was conducted in two phases: the first one involved a cross-sectional survey using an instrument developed by the IOF which was tailored to local needs, and the second consisted of a focus group in a hybrid format. Results The twenty participants were diagnosed with osteoporosis for less than 3 years, most of them received treatment and did not fracture. Treating physicians was the most trusted source of information, while influencers and media were seen as unreliable. Osteoporosis had a moderate impact on patients’ quality of life, with only a few requiring help with daily chores. The qualitative phase revealed that patients who received care at private institutions had better access to information about the disease and treatment options. Despite the minimal impact on their current quality of life, patients showed concern about future risks like falls and loss of independence. Conclusion Being diagnosed with osteoporosis has a significant impact on people’s daily life, independently whether a fracture occurred, received treatment, embraced a healthy bone lifestyle or trust own treating physician. Fear of fractures and their consequences underly patients’ perceptions which is seen as not considered enough by physicians, health authorities, drug companies, NGOs and media.
- Open Access
- 7 July 2025
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 132 (11) , 1596-1605
Premenstrual Dysphoric Disorder Prevalence and Symptoms Across Age Groups: A Cross‐Sectional Study
Objective: To estimate the prevalence and symptom severity of premenstrual dysphoric disorder (PMDD) in Brazilian women according to age groups, and to conduct an association analysis between psychoemotional and somatic symptoms. Design: Cross‐sectional study. Setting: 303 private clinics across Brazil. Population: 45 160 women aged 20–49 years. Methods: Self‐report questionnaire regarding the prevalence and intensity of premenstrual symptoms. Statistical analysis performed using Pearson's chi‐square test and Poisson regression and multiple logistic regression. Main Outcome Measures: Prevalence and intensity of somatic and psychoemotional premenstrual symptoms. Results: Prevalence of PMDD was 3.57% (95% CI: 3.40–3.75). Psychoemotional symptoms were more prevalent than somatic symptoms, with anxiety/tension (99.9%) and irritability/anger (99.8%) being the most frequently reported symptoms. Weight gain (92.5%) and edema (92.1%) were the most prevalent somatic symptoms. Anxiety/tension and headache occurred independently of other symptoms. Binge eating was associated with weight gain (OR = 2.77, 95% CI [2.11, 3.62]), acne (OR = 2.37, 95% CI [1.79, 3.10]), immunoallergic exacerbations (OR = 1.81, 95% CI [1.26, 2;60]) and edema (OR—0.74, 95% CI [0.55, 0.97]). Affective lability was associated with immunoallergic exacerbations (OR = 1.49, 95% CI [1.16, 1.91]) and mastalgia (OR = 1.29, 95% CI [1.02, 1.63]). Depression was associated with acne (OR = 0.72, 95% CI [0.57, 0.89]) and weight gain (OR = 0.77, 95% CI [0.61, 0.96]). Conclusions: The prevalence of PMDD was consistent with other population studies. Psychoemotional symptoms were more prevalent. Association analysis provided new insights into premenstrual symptomatology.
- 7 July 2025
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 132 (11) , 1596-1605
Open AccessPremenstrual Dysphoric Disorder Prevalence and Symptoms Across Age Groups: A Cross‐Sectional Study
Objective: To estimate the prevalence and symptom severity of premenstrual dysphoric disorder (PMDD) in Brazilian women according to age groups, and to conduct an association analysis between psychoemotional and somatic symptoms. Design: Cross‐sectional study. Setting: 303 private clinics across Brazil. Population: 45 160 women aged 20–49 years. Methods: Self‐report questionnaire regarding the prevalence and intensity of premenstrual symptoms. Statistical analysis performed using Pearson's chi‐square test and Poisson regression and multiple logistic regression. Main Outcome Measures: Prevalence and intensity of somatic and psychoemotional premenstrual symptoms. Results: Prevalence of PMDD was 3.57% (95% CI: 3.40–3.75). Psychoemotional symptoms were more prevalent than somatic symptoms, with anxiety/tension (99.9%) and irritability/anger (99.8%) being the most frequently reported symptoms. Weight gain (92.5%) and edema (92.1%) were the most prevalent somatic symptoms. Anxiety/tension and headache occurred independently of other symptoms. Binge eating was associated with weight gain (OR = 2.77, 95% CI [2.11, 3.62]), acne (OR = 2.37, 95% CI [1.79, 3.10]), immunoallergic exacerbations (OR = 1.81, 95% CI [1.26, 2;60]) and edema (OR—0.74, 95% CI [0.55, 0.97]). Affective lability was associated with immunoallergic exacerbations (OR = 1.49, 95% CI [1.16, 1.91]) and mastalgia (OR = 1.29, 95% CI [1.02, 1.63]). Depression was associated with acne (OR = 0.72, 95% CI [0.57, 0.89]) and weight gain (OR = 0.77, 95% CI [0.61, 0.96]). Conclusions: The prevalence of PMDD was consistent with other population studies. Psychoemotional symptoms were more prevalent. Association analysis provided new insights into premenstrual symptomatology.
- 27 June 2025
- Published by Wolters Kluwer Health in Menopause
- Vol. 32 (7) , 610-620
Correlation between equol production and intestinal microbiota after treatment with isoflavone, isoflavone plus probiotic and hormonal therapy in postmenopausal women: a pilot study
Objectives: To correlate the urinary excretion of equol with intestinal microbiota in response to isoflavone supplementation alone or in combination with probiotics, and to compare these results with those of hormone therapy in postmenopausal women. Methods: A pilot study was conducted on 47 postmenopausal women aged 40-60 years. Participants were randomly assigned to one of three groups: (A) oral isoflavone (150 mg dry extract of Glycine max ); (B) isoflavone plus probiotic ( Lactobacillus acidophilus , Lactobacillus casei , Lactococcus lactis , Bifidobacterium bifidum , and Bifidobacterium lactis ); or (C) hormone therapy (1 mg estradiol/0.5 mg norethisterone acetate). Fecal samples were collected to extract bacterial DNA, and equol and its intermediates were measured using gas chromatography coupled with mass spectrometry at baseline and after 16 weeks of treatment. Results: In the isoflavone alone and isoflavone plus probiotic groups, no statistically significant correlations were found between bacterial phyla or genera and the urinary excretion of equol or its intermediate after 16 weeks of treatment. In the hormone therapy group, directly proportional correlation between Bacteroidetes (Spearman R =0.83, Pa=0.01), Cyanobacteria (Spearman R =0.89, Pa=0.002), Alistipes (Spearman R =0.81, Pa=0.04), Catenibacterium (Spearman R =0.81, Pa=0.04), Clostridium (Spearman R =0.84, Pa=0.02), Barnesiella (Spearman R =0.84, Pa=0.02), and the urinary excretion of the equol intermediate were observed. Conclusions: Only the hormone therapy group showed a significant increase in bacterial abundance involved in isoflavone metabolism.
- 27 June 2025
- Published by Wolters Kluwer Health in Menopause
- Vol. 32 (7) , 610-620
Correlation between equol production and intestinal microbiota after treatment with isoflavone, isoflavone plus probiotic and hormonal therapy in postmenopausal women: a pilot study
Objectives: To correlate the urinary excretion of equol with intestinal microbiota in response to isoflavone supplementation alone or in combination with probiotics, and to compare these results with those of hormone therapy in postmenopausal women. Methods: A pilot study was conducted on 47 postmenopausal women aged 40-60 years. Participants were randomly assigned to one of three groups: (A) oral isoflavone (150 mg dry extract of Glycine max ); (B) isoflavone plus probiotic ( Lactobacillus acidophilus , Lactobacillus casei , Lactococcus lactis , Bifidobacterium bifidum , and Bifidobacterium lactis ); or (C) hormone therapy (1 mg estradiol/0.5 mg norethisterone acetate). Fecal samples were collected to extract bacterial DNA, and equol and its intermediates were measured using gas chromatography coupled with mass spectrometry at baseline and after 16 weeks of treatment. Results: In the isoflavone alone and isoflavone plus probiotic groups, no statistically significant correlations were found between bacterial phyla or genera and the urinary excretion of equol or its intermediate after 16 weeks of treatment. In the hormone therapy group, directly proportional correlation between Bacteroidetes (Spearman R =0.83, Pa=0.01), Cyanobacteria (Spearman R =0.89, Pa=0.002), Alistipes (Spearman R =0.81, Pa=0.04), Catenibacterium (Spearman R =0.81, Pa=0.04), Clostridium (Spearman R =0.84, Pa=0.02), Barnesiella (Spearman R =0.84, Pa=0.02), and the urinary excretion of the equol intermediate were observed. Conclusions: Only the hormone therapy group showed a significant increase in bacterial abundance involved in isoflavone metabolism.
- 1 February 2025
- Published by Wolters Kluwer Health in Menopause
- Vol. 32 (2) , 134-141
Prevalence and predictors of genitourinary syndrome of menopause: a population-based study in middle-aged Brazilian women
Objective: This study aimed to determine the prevalence and predictors of genitourinary syndrome of menopause (GSM) in Brazilian women. Methods: A cross-sectional population-based household survey was conducted among 749 women aged 45 to 60 years. The dependent variable was the presence of GSM, which was assessed using a pretested structured questionnaire. The independent variables included sociodemographic data, health-related habits and morbidities, self-perception of health, and gynecological background. Results: The mean age of the participants was 52.5 ± 4.4 years, and the mean age of menopause was 46.4 ± 6.2 years. GSM was prevalent in 51.4% of the women. The most prevalent symptoms were dyspareunia (35%), daily vaginal dryness (25.1%), and intercourse vaginal dryness (24%). Poisson regression analysis demonstrated that global GSM was associated with having a partner, topical estrogen treatment (TET), depression/anxiety, and rheumatological diseases. The genital symptoms of GSM were related to peri/postmenopausal status, TET, multimorbidity, sexual activity, and the absence of vaginal birth. Factors associated with GSM urinary symptoms were negative self-perception of health, having at least one vaginal birth, depression/anxiety, and rheumatological diseases. Sexual symptoms were associated with having a partner, using TET, depression/anxiety, and rheumatic disease. GSM affected the lives of 42.8% of the women to some degree, and 43% discussed their symptoms with their gynecologists. Conclusions: GSM was prevalent in half of the women in this study, and several factors were associated with its presence. These results highlight the compelling need to understand these factors, improve diagnoses, and increase access to treatment.
- 1 February 2025
- Published by Wolters Kluwer Health in Menopause
- Vol. 32 (2) , 134-141
Prevalence and predictors of genitourinary syndrome of menopause: a population-based study in middle-aged Brazilian women
Objective: This study aimed to determine the prevalence and predictors of genitourinary syndrome of menopause (GSM) in Brazilian women. Methods: A cross-sectional population-based household survey was conducted among 749 women aged 45 to 60 years. The dependent variable was the presence of GSM, which was assessed using a pretested structured questionnaire. The independent variables included sociodemographic data, health-related habits and morbidities, self-perception of health, and gynecological background. Results: The mean age of the participants was 52.5 ± 4.4 years, and the mean age of menopause was 46.4 ± 6.2 years. GSM was prevalent in 51.4% of the women. The most prevalent symptoms were dyspareunia (35%), daily vaginal dryness (25.1%), and intercourse vaginal dryness (24%). Poisson regression analysis demonstrated that global GSM was associated with having a partner, topical estrogen treatment (TET), depression/anxiety, and rheumatological diseases. The genital symptoms of GSM were related to peri/postmenopausal status, TET, multimorbidity, sexual activity, and the absence of vaginal birth. Factors associated with GSM urinary symptoms were negative self-perception of health, having at least one vaginal birth, depression/anxiety, and rheumatological diseases. Sexual symptoms were associated with having a partner, using TET, depression/anxiety, and rheumatic disease. GSM affected the lives of 42.8% of the women to some degree, and 43% discussed their symptoms with their gynecologists. Conclusions: GSM was prevalent in half of the women in this study, and several factors were associated with its presence. These results highlight the compelling need to understand these factors, improve diagnoses, and increase access to treatment.
- Open Access
- 25 September 2024
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 168 (3) , 1221-1228
Impact of age on premenstrual syndrome prevalence and severity: A population‐based survey in Brazil
Objective: To evaluate the relationship between premenstrual disorders (PMD) and age, we analyzed the prevalence and severity of psycho‐emotional and physical symptoms in a representative sample of Brazilian women. Methods: This observational and retrospective study analyzed data from Brazilian women aged 20–49 years from five regions of the country who reported premenstrual symptoms. Participants completed a premenstrual symptom screening questionnaire and self‐reported the presence and severity of their symptoms. Among 23 104 women reporting does premenstrual symptoms, 38.91% ( n = 8990) experienced PMD caused functional impairment. Finally, 5121 participants agreed to complete the adapted version of the screening questionnaire. Results: The age group distribution was 20–29 (46.7%), 30–39 (38.3%), and 40–49 years (15%). The most prevalent and severe physical symptom was acne/oily skin in participants aged 20–29 years and headache in women aged 30–49 years. Regarding psycho‐emotional symptoms, the most prevalent was anxiety/tension in women aged 20–29 years and 40–49 years and irritability/anger in those aged 30–39 years. Irritability/anger was the most severe symptom in all groups. Conclusion: PMD significantly impacts the quality of life of Brazilian women with varying intensity. Physical symptoms associated with PMD vary with age, while psycho‐emotional symptoms, particularly irritability/anger and anxiety, were intense in Brazilian women of reproductive age. These findings inform early diagnosis and individualized treatment approaches for PMD, addressing the needs of women.
- 25 September 2024
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 168 (3) , 1221-1228
Open AccessImpact of age on premenstrual syndrome prevalence and severity: A population‐based survey in Brazil
Objective: To evaluate the relationship between premenstrual disorders (PMD) and age, we analyzed the prevalence and severity of psycho‐emotional and physical symptoms in a representative sample of Brazilian women. Methods: This observational and retrospective study analyzed data from Brazilian women aged 20–49 years from five regions of the country who reported premenstrual symptoms. Participants completed a premenstrual symptom screening questionnaire and self‐reported the presence and severity of their symptoms. Among 23 104 women reporting does premenstrual symptoms, 38.91% ( n = 8990) experienced PMD caused functional impairment. Finally, 5121 participants agreed to complete the adapted version of the screening questionnaire. Results: The age group distribution was 20–29 (46.7%), 30–39 (38.3%), and 40–49 years (15%). The most prevalent and severe physical symptom was acne/oily skin in participants aged 20–29 years and headache in women aged 30–49 years. Regarding psycho‐emotional symptoms, the most prevalent was anxiety/tension in women aged 20–29 years and 40–49 years and irritability/anger in those aged 30–39 years. Irritability/anger was the most severe symptom in all groups. Conclusion: PMD significantly impacts the quality of life of Brazilian women with varying intensity. Physical symptoms associated with PMD vary with age, while psycho‐emotional symptoms, particularly irritability/anger and anxiety, were intense in Brazilian women of reproductive age. These findings inform early diagnosis and individualized treatment approaches for PMD, addressing the needs of women.
- 26 February 2024
- Published by Wolters Kluwer Health in Menopause
- Vol. 31 (4) , 288-302
Comparison of the effect of noninvasive radiofrequency with vaginal estrogen and vaginal moisturizer in the treatment of vulvovaginal atrophy in postmenopausal women: a randomized clinical trial
Objective: To compare the effect of noninvasive radiofrequency (RF) with vaginal estrogen (E), and vaginal moisturizer (M) on improving vulvovaginal atrophy (VVA) in women with genitourinary syndrome of menopause. Methods: A total of 32 postmenopausal women who met the inclusion criteria were randomized into three intervention arms to receive one of the following treatments: three sessions of noninvasive RF therapy (RF arm); intravaginal estriol cream 1 mg applied daily for 2 weeks, followed by 1 mg applied two times weekly or 1 mg of estradiol vaginal fast-dissolving film applied daily for 2 weeks, followed by 1 mg applied two times weekly (E arm); and intravaginal moisturizer two times a week (M arm). Assessments at baseline and after 4 months were conducted using Vaginal Health Index score, Vaginal Maturation, visual analog scale for VVA symptoms (dyspareunia, dryness, and burning), and Menopause Rating Scale (MRS) for urogenital symptoms. Vaginal wall biopsies were administered to participants who consented, pretreatment and posttreatment (at baseline and after 4 months of follow-up). Results: After 4 months, the Vaginal Health Index showed an increase of 6.6 points in mean total score in the RF arm, also in the E arm (+7.3 points), with no significant improvement in the M arm (+1.5 points) (interaction effect: RF, E ≠ M, P < 0.001). Regarding vaginal maturation, there was a significant increase in superficial cells in the E arm (+31.3), with no significant changes in the RF (+9.3) and M (−0.5) arms (interaction effect: E ≠ M, P < 0.001). Vaginal pH decreased significantly in the E arm (−1.25), with a similar response in the RF arm (−1.7), with no significant improvement in the M arm (−0.25) (interaction effect: RF, E ≠ M, P < 0.001). There was a significant improvement in the MRS score for VVA symptoms in the three intervention arms, with no predominance of any arm, whereas the improvement in the total MRS score for urogenital symptoms showed a predominance of the RF arm (ΔRF: −7.8; ΔE: −3.5; ΔM: −2.3; RF ≠ E, M). According to histopathologic analysis, there was no statistically significant increase in glycogenation (P = 0.691) or epithelial cone height (P = 0.935), despite an increase in the median delta (difference between pretreatment and posttreatment) in the three intervention arms (glycogenation: RF arm Δ = +118.4%; E arm Δ = +130.9%; M arm Δ = +24.9%; epithelial cone height: RF arm Δ = +33.5%; E arm Δ = +18.6%; M arm Δ = +22.3%). Conclusion: The effect of noninvasive RF on the treatment of vulvovaginal symptoms of genitourinary syndrome of menopause was similar to vaginal estrogen, except for hormonal cytology, and superior to vaginal moisturizer, with improvement in some histomorphometric parameters. These findings are promising, especially for the population that cannot or prefers not to use vaginal estrogen therapy.
- 26 February 2024
- Published by Wolters Kluwer Health in Menopause
- Vol. 31 (4) , 288-302
Comparison of the effect of noninvasive radiofrequency with vaginal estrogen and vaginal moisturizer in the treatment of vulvovaginal atrophy in postmenopausal women: a randomized clinical trial
Objective: To compare the effect of noninvasive radiofrequency (RF) with vaginal estrogen (E), and vaginal moisturizer (M) on improving vulvovaginal atrophy (VVA) in women with genitourinary syndrome of menopause. Methods: A total of 32 postmenopausal women who met the inclusion criteria were randomized into three intervention arms to receive one of the following treatments: three sessions of noninvasive RF therapy (RF arm); intravaginal estriol cream 1 mg applied daily for 2 weeks, followed by 1 mg applied two times weekly or 1 mg of estradiol vaginal fast-dissolving film applied daily for 2 weeks, followed by 1 mg applied two times weekly (E arm); and intravaginal moisturizer two times a week (M arm). Assessments at baseline and after 4 months were conducted using Vaginal Health Index score, Vaginal Maturation, visual analog scale for VVA symptoms (dyspareunia, dryness, and burning), and Menopause Rating Scale (MRS) for urogenital symptoms. Vaginal wall biopsies were administered to participants who consented, pretreatment and posttreatment (at baseline and after 4 months of follow-up). Results: After 4 months, the Vaginal Health Index showed an increase of 6.6 points in mean total score in the RF arm, also in the E arm (+7.3 points), with no significant improvement in the M arm (+1.5 points) (interaction effect: RF, E ≠ M, P < 0.001). Regarding vaginal maturation, there was a significant increase in superficial cells in the E arm (+31.3), with no significant changes in the RF (+9.3) and M (−0.5) arms (interaction effect: E ≠ M, P < 0.001). Vaginal pH decreased significantly in the E arm (−1.25), with a similar response in the RF arm (−1.7), with no significant improvement in the M arm (−0.25) (interaction effect: RF, E ≠ M, P < 0.001). There was a significant improvement in the MRS score for VVA symptoms in the three intervention arms, with no predominance of any arm, whereas the improvement in the total MRS score for urogenital symptoms showed a predominance of the RF arm (ΔRF: −7.8; ΔE: −3.5; ΔM: −2.3; RF ≠ E, M). According to histopathologic analysis, there was no statistically significant increase in glycogenation (P = 0.691) or epithelial cone height (P = 0.935), despite an increase in the median delta (difference between pretreatment and posttreatment) in the three intervention arms (glycogenation: RF arm Δ = +118.4%; E arm Δ = +130.9%; M arm Δ = +24.9%; epithelial cone height: RF arm Δ = +33.5%; E arm Δ = +18.6%; M arm Δ = +22.3%). Conclusion: The effect of noninvasive RF on the treatment of vulvovaginal symptoms of genitourinary syndrome of menopause was similar to vaginal estrogen, except for hormonal cytology, and superior to vaginal moisturizer, with improvement in some histomorphometric parameters. These findings are promising, especially for the population that cannot or prefers not to use vaginal estrogen therapy.